TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a HUMIMIC Chip infectable with Mycobacterium tuberculosis. This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment. TissUse announced today that it has received funding from the Bill & Melinda Gates Foundation […]
continue readingPhilip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract
PMI and TissUse have signed a collaboration agreement to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. The two partners will develop a highly innovative integrated human aerosol test platform that emulates the entire human respiratory […]
continue readingTissUse GmbH appoints Dr. Reyk Horland as new CEO while TissUse’s founder
On its 10th company anniversary, TissUse GmbH appoints Dr. Reyk Horland, previously VP Business Development, as the new CEO. Reyk Horland has been with TissUse since it was founded in 2010 and has implemented a profitable product business with a remarkable annual sales growth rate since the market launch of the HUMIMIC® technology in 2014. […]
continue reading
TissUse launcht neue Produktmarkte HUMIMIC
TissUse, die Berliner Pioniere in Human-on-a-Chip Entwicklungen haben Ihre Produktmarke HUMIMIC gelauncht. Unter diesem Brand werden in Zukunft alle Produkte des Unternehmens gebündelt. Unter der Marke HUMIMIC bekommen die Produkte der TissUse GmbH ab sofort einen einheitlichen Auftritt und eine einheitliche Bezeichnung. Dadurch wird es für Kunden noch einfacher zu erkennen, welches Produkt für den […]
continue reading